First trimester biochemistry at different maternal ages

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 3, 2012, Pages 549-555

  Ranta, Jenni K ^a,b   Marttala, Jaana ^c   Laitinen, Pivi ^c,d   Kultti, Johanna ^e   Kauhanen, Olavi ^f   Romppanen, Jarkko ^a,b   Hmlinen, Esa ^g,h   Heinonen, Seppo ^a,f   Pulkki, Kari ^a,b   Ryynnen, Markku ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b OK Kuopio   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d Central Ostrobothnia Hospital District   (Finland)

^e Seinjoki Central Hospital   (Finland)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Down syndrome; first trimester; free hCG; gestational age; maternal age; PAPP A; screening

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; CHEMICAL ANALYSIS; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; MATERNAL AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING TEST; TASK PERFORMANCE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; YOUNG ADULT;

EID: 84860474588     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.785     Document Type: Article

References (26)

1. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000;96:207-13. (Pubitemid 30447340)
2. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH. Onestop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002;20:219-25.
3. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-13. (Pubitemid 37211055)
4. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353(19):2001-11. (Pubitemid 41609093)
5. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
6. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH. Prospective validation of fi rst-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009;34:14-18.
7. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the fi rst trimester: a Scottish multicentre study. Br J Obstet Gynaecol 2002;109:667-76. (Pubitemid 37329279)
8. Palomaki GE, Bradley LA, McDowell GA. Down Syndrome Working Group; ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: prenatal screening for Down syndrome. Genet Med 2005;7:344-54.
9. Koster MP, Wortelboer EJ, Engels MA, Stoutenbeek PH, Elvers LH, Visser GH, et al. Quality of nuchal translucency measurements in The Netherlands: a quantitative analysis. Ultrasound Obstet Gynecol 2009;34:136-41.
10. Palomaki GE, Lee JE, Canick JA, McDowell GA, Donnenfeld AE. ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: prenatal screening for Down syndrome that includes fi rst-trimester biochemistry and/or ultrasound measurements. Genet Med 2009;11:669-81.
11. Lambert-Messerlian GM, Eklund EE, Malone FD, Palomaki GE, Canick JA, D'Alton ME. Stability of fi rst- and secondtrimester serum markers after storage and shipment. Prenat Diagn 2006;26:17-21. (Pubitemid 43189326)
12. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol 1996;174:612-6. (Pubitemid 26070151)
13. de Graaf IM, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS, van Lith JM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999;19:458-62. (Pubitemid 29224437)
14. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104. (Pubitemid 36734906)
15. Brambati B, Macintosh MC, Teisner B, Maguiness S, Shrimanker K, Lanzani A, et al. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the fi rst trimester in association with abnormal fetal karyotype. Br J Obstet Gynaecol 1993;100:324-6. (Pubitemid 23121151)
16. Reynolds TM, Nix AB, Dunstan FD, Dawson AJ. Age-specifi c detection and false-positive rates: an aid to counseling in Down syndrome risk screening. Obstet Gynecol 1993;81:447-50. (Pubitemid 23085309)
17. Spencer K. Age related detection and false-positive rates when screening for Down's syndrome in the fi rst trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A. Br J Obstet Gynaecol 2001;108:1043-6. (Pubitemid 32971737)
18. Centini G, Rosignoli L, Scarinci R, Faldini E, Morra C, Centini G, et al. Re-evaluation of risk for Down syndrome by means of the combined test in pregnant women of 35 years or more. Prenat Diagn 2005;25:133-6. (Pubitemid 40327393)
19. The database of Finnish Acts of Parliament. Government Decree on Screenings (1339/2006). Accessed November 18, 2011. Available at: http://www.fi nlex.fi /en/laki/kaannokset/2006/en20061339.
20. World Medical Association. Declaration of Helsinki. Ethical guidelines. National Institutes of Health, Offi ce of Human Subjects Research. Accessed November 18, 2011. Available at: http://ohsr.od.nih.gov/guidelines/helsinki. html.
21. Wright D, Spencer K, Kagan KK, T ø rring N, Petersen OB, Christou A, et al. First-trimester combined screening for trisomy 21 at 7-14 weeks'gestation. Ultrasound Obstet Gynecol 2010;36:404-11.
22. T ø rring N. Performance of fi rst-trimester screening between gestational weeks 7 and 13. Clin Chem 2009;55:1564-7.
23. Koster MP, Wortelboer EJ, Stoutenbeek P, Visser GH, Schielen PC. Modeling the Down syndrome screening performance using fi rst trimester serum markers. Ultrasound Obstet Gynecol 2011;38:134-9. doi: 10.1002/uog.8881.
24. Ranta JK, Raatikainen K, Romppanen J, Pulkki K, Heinonen S. Increased time-to-pregnancy and fi rst trimester Down's syndrome screening. Hum Reprod 2010;25:412-7.
25. van Ravenswaaij R, Tesselaar-van der Goot M, de Wolf S, van Leeuwen-Spruijt M, Visser GH, Schielen PC. First-trimester serum PAPP-A and f hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome. Prenat Diagn 2011;31: 50-7.
26. Tislaric-Medenjak D, Zec I, Simundic AM, Sabolovic-Rudman S, Kos M, Megla ZB. The impact of temporal variability of biochemical markers PAPP-A and free beta-hCG on the specifi city of the fi rst-trimester Down syndrome screening: a Croatian retrospective study. BMC Res Notes 2010;3:194-9.